
样式: 排序: IF: - GO 导出 标记为已读
-
Transoral Robotic Surgery for Recurrent Tumors of the Upper Aerodigestive Tract (RECUT): An International Cohort Study J. Natl. Cancer Inst. (IF 11.816) Pub Date : 2022-08-10 John C Hardman, F Chris Holsinger, Grainne C Brady, Avinash Beharry, Alec T Bonifer, Gregoire D’Andréa, Surender K Dabas, John R de Almeida, Umamaheswar Duvvuri, Peter Floros, Tamer A Ghanem, Philippe Gorphe, Neil D Gross, David Hamilton, Chareeni Kurukulasuriya, Mikkel Hjordt Holm Larsen, Daniel J Lin, J Scott Magnuson, Jeroen Meulemans, Brett A Miles, Eric J Moore, Gouri Pantvaidya, Scott Roof, Niclas
Background Transoral robotic surgery (TORS) is an emerging minimally invasive surgical treatment for residual, recurrent, and new primary head and neck cancers in previously irradiated fields, with limited evidence for its oncological effectiveness. Methods A retrospective observational cohort study of consecutive cases performed in 16 high-volume international centers before August 2018 was conducted
-
The oral microbiome and lung cancer risk: An analysis of 3 prospective cohort studies J. Natl. Cancer Inst. (IF 11.816) Pub Date : 2022-08-05 Emily Vogtmann, Xing Hua, Guoqin Yu, Vaishnavi Purandare, Autumn G Hullings, Dantong Shao, Yunhu Wan, Shilan Li, Casey L Dagnall, Kristine Jones, Belynda D Hicks, Amy Hutchinson, J Gregory Caporaso, William Wheeler, Dale P Sandler, Laura E Beane Freeman, Linda M Liao, Wen-Yi Huang, Neal D Freedman, Neil E Caporaso, Rashmi Sinha, Mitchell H Gail, Jianxin Shi, Christian C Abnet
Background Previous studies suggested associations between the oral microbiome and lung cancer, but studies were predominantly cross-sectional and underpowered. Methods Using a case-cohort design, 1,306 incident lung cancer cases were identified in the Agricultural Health Study, NIH-AARP Diet and Health Study, and Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. Referent subcohorts were
-
Discoidin domain receptor-driven gene signatures as markers of patient response to anti-PD-L1 immune checkpoint therapy J. Natl. Cancer Inst. (IF 11.816) Pub Date : 2022-08-03 Sungyong You, Minhyung Kim, Xen Ping Hoi, Yu Cheng Lee, Li Wang, David Spetzler, Jim Abraham, Dan Magee, Prerna Jain, Matthew D Galsky, Keith Syson Chan, Dan Theodorescu
Background Anti-PD-1/PD-L1 immune checkpoint therapies (ICTs) only provided durable responses in a subset of cancer patients. Thus, biomarkers are needed to predict non-responders and offer them alternative treatments. We recently implicated discoidin domain receptor tyrosine kinase 2 (DDR2) as a contributor to anti-PD-1 resistance in animal models; therefore, we sought to investigate if this gene
-
Mediators of Racial Disparities in Heart Dose among Whole Breast Radiotherapy Patients. J. Natl. Cancer Inst. (IF 11.816) Pub Date : 2022-08-02 Christina Hunter Chapman,Reshma Jagsi,Kent A Griffith,Jean M Moran,Frank Vicini,Eleanor Walker,Michael Dominello,Eyad Abu-Isa,James Hayman,Anna M Laucis,Melissa Mietzel,Lori Pierce,
BACKGROUND Racial disparities in survival of patients with cancer motivate research to quantify treatment disparities and evaluate multilevel determinants. Prior research has not evaluated cardiac radiation dose in large cohorts of breast cancer patients by race, nor examined potential causes or implications of dose disparities. METHODS We used a statewide consortium database to consecutively sample
-
Variation in Cardiac Dose Explains a "Fraction" of the Disparities among Breast Cancer Patients. J. Natl. Cancer Inst. (IF 11.816) Pub Date : 2022-08-02 Rinaa S Punglia,Michael J Hassett
-
Surveillance imaging vs symptomatic recurrence detection and survival in stage II-III breast cancer (AFT-01). J. Natl. Cancer Inst. (IF 11.816) Pub Date : 2022-08-01 Jessica R Schumacher,Heather B Neuman,Menggang Yu,David J Vanness,Yajuan Si,Elizabeth S Burnside,Kathryn J Ruddy,Ann H Partridge,Deborah Schrag,Stephen B Edge,Ying Zhang,Elizabeth A Jacobs,Jeffrey Havlena,Amanda B Francescatti,David P Winchester,Daniel P McKellar,Patricia A Spears,Benjamin D Kozower,George J Chang,Caprice C Greenberg,
BACKGROUND Guidelines for follow-up after locoregional breast cancer treatment recommend imaging for distant metastases only in the presence of patient signs/symptoms. However, guidelines have not been updated to reflect advances in imaging, systemic therapy, or understanding of biological subtype. We assessed the association between mode of distant recurrence detection and survival. METHODS In this
-
Encouraging Rigorous Patient-Generated Data All along the Drug Development Continuum. J. Natl. Cancer Inst. (IF 11.816) Pub Date : 2022-07-28 Vishal Bhatnagar,Paul G Kluetz
-
Shifting the Paradigm: Reimagining Approaches to Diversifying the Leadership of the Nation's Cancer Centers. J. Natl. Cancer Inst. (IF 11.816) Pub Date : 2022-07-28 Loren Saulsberry,Olufunmilayo I Olopade
-
Listening to the patient voice adds value to cancer clinical trials J. Natl. Cancer Inst. (IF 11.816) Pub Date : 2022-07-28 Michael D Brundage, Norah L Crossnohere, Jennifer O’Donnell, Samantha Cruz Rivera, Roger Wilson, Albert W Wu, Moher David, Derek Kyte, Bryce B Reeve, Alexandra Gilbert, Ronald C Chen, Melanie J Calvert, Claire Snyder
Randomized clinical trials are critical for evaluating the safety and efficacy of interventions in oncology and informing regulatory decisions, practice guidelines, and health policy. Patient-reported outcomes (PROs) are increasingly used in randomized trials to reflect the impact of receiving cancer therapies from the patient perspective and can inform evaluations of interventions by providing evidence
-
Leadership Diversity and Development in the Nation’s Cancer Centers J. Natl. Cancer Inst. (IF 11.816) Pub Date : 2022-07-28 Caryn Lerman, Chanita Hughes-Halbert, Mary Falcone, David M Gosky, Roy A Jensen, Kelvin P Lee, Edith Mitchell, Kunle Odunsi, Jennifer W Pegher, Elisa Rodriguez, Yolanda Sanchez, Reuben Shaw, George Weiner, Cheryl L Willman
The capacity and diversity of the oncology leadership workforce has not kept pace with the emerging needs of our increasingly complex cancer centers and the spectrum of challenges our institutions face in reducing the cancer burden in diverse catchment areas. Recognizing the importance of a diverse workforce to reduce cancer inequities, the Association of American Cancer Institutes conducted a survey
-
Cancer Risk Prediction Paradigm Shift: Using Artificial Intelligence to Improve Performance and Health Equity. J. Natl. Cancer Inst. (IF 11.816) Pub Date : 2022-07-25 Christoph I Lee,Joann G Elmore
-
Deep Learning vs Traditional Breast Cancer Risk Models to Support Risk-Based Mammography Screening J. Natl. Cancer Inst. (IF 11.816) Pub Date : 2022-07-25 Constance D Lehman, Sarah Mercaldo, Leslie R Lamb, Tari A King, Leif W Ellisen, Michelle Specht, Rulla M Tamimi
Background Deep learning breast cancer risk models demonstrate improved accuracy compared to traditional risk models but have not been prospectively tested. We compared the accuracy of a deep learning risk score derived from the patient’s prior mammogram to traditional risk scores to prospectively identify patients with cancer in a cohort due for screening. Methods We collected data on 119,139 bilateral
-
Sociodemographic survival disparities for lung cancer in the United States, 2000–2016 J. Natl. Cancer Inst. (IF 11.816) Pub Date : 2022-07-22 Andrew F Brouwer, Jason M Engle, Jihyoun Jeon, Rafael Meza
Background Understanding the impact of patient and tumor characteristics on lung cancer survival can help to build personalized prognostic models and identify health disparities. Methods We identified 557,555 patients aged 25+ years diagnosed with lung/bronchus carcinoma from the SEER database, 2000–2016. We estimated hazard ratios (HR) for demographic (sex, age, race and ethnicity), tumor (stage,
-
Vaginal Estrogen Therapy for the Genitourinary Symptoms of Menopause: Caution or Reassurance? J. Natl. Cancer Inst. (IF 11.816) Pub Date : 2022-07-20 Elizabeth J Cathcart-Rake,Kathryn J Ruddy
-
Systemic or Vaginal Hormone Therapy After Early Breast Cancer: A Danish Observational Cohort Study J. Natl. Cancer Inst. (IF 11.816) Pub Date : 2022-07-20 Søren Cold, Frederik Cold, Maj-Britt Jensen, Deirdre Cronin-Fenton, Peer Christiansen, Bent Ejlertsen
Background Women treated for breast cancer (BC) often suffer genitourinary syndrome of menopause. These symptoms may be alleviated by vaginal estrogen therapy (VET) or menopausal hormone therapy (MHT). However, there are concerns of risks of recurrence of BC and death following treatment. Methods Our study included longitudinal data from a national cohort of postmenopausal women, diagnosed 1997-2004
-
A Randomized Trial of Telephone-Based Smoking Cessation Treatment in the Lung Cancer Screening Setting. J. Natl. Cancer Inst. (IF 11.816) Pub Date : 2022-07-12 Kathryn L Taylor,Randi M Williams,Tengfei Li,George Luta,Laney Smith,Kimberly M Davis,Cassandra Stanton,Raymond Niaura,David Abrams,Tania Lobo,Jeanne Mandelblatt,Jinani Jayasekera,Rafael Meza,Jihyoun Jeon,Pianpian Cao,Eric D Anderson,
BACKGROUND Lung cancer mortality is reduced via low-dose CT screening and treatment of early-stage disease. Evidence-based smoking cessation treatment in the lung screening setting can further reduce mortality. We report the results of a cessation trial from the NCI's SCALE collaboration. METHODS Eligible patients (N = 818) aged 50-80 were randomized (May 2017-January 2021) to the Intensive vs. Minimal
-
Predictive role of CD36 expression in HER2-positive breast cancer patients receiving neoadjuvant trastuzumab J. Natl. Cancer Inst. (IF 11.816) Pub Date : 2022-07-05 Francesca Ligorio, Serena Di Cosimo, Paolo Verderio, Chiara Maura Ciniselli, Sara Pizzamiglio, Lorenzo Castagnoli, Matteo Dugo, Barbara Galbardi, Roberto Salgado, Sherene Loi, Stefan Michiels, Tiziana Triulzi, Elda Tagliabue, Sarra El-Abed, Miguel Izquierdo, Evandro de Azambuja, Paolo Nuciforo, Jens Huober, Luca Moscetti, Wolfgang Janni, Maria Antonia Coccia-Portugal, Paola Antonia Corsetto, Antonino
Background Despite huge efforts to identify biomarkers associated with long-term clinical outcomes in patients with early-stage Human Epidermal growth factor Receptor 2 (HER2)-positive Breast Cancer (HER2+ BC) treated with (neo)adjuvant anti-HER2 therapy, no reliable predictors have been identified so far. Fatty Acid uptake, a process mediated by the transmembrane transporter CD36, has recently emerged
-
Radiotherapy-related dose and irradiated volume effects on breast cancer risk among Hodgkin lymphoma survivors J. Natl. Cancer Inst. (IF 11.816) Pub Date : 2022-06-30 Sander Roberti, Flora E van Leeuwen, Cécile M Ronckers, Inge M Krul, Florent de Vathaire, Cristina Veres, Ibrahima Diallo, Cécile P M Janus, Berthe M P Aleman, Nicola S Russell, Michael Hauptmann
Background Breast cancer (BC) risk is increased among Hodgkin lymphoma (HL) survivors treated with chest radiotherapy. Case-control studies showed a linear radiation dose-response relationship for estimated dose to the breast tumor location. However, these relative risks cannot be used for absolute risk prediction of BC anywhere in the breasts. Furthermore, the independent and joint effects of radiation
-
Distinct reproductive risk profiles for intrinsic-like breast cancer subtypes: pooled analysis of population-based studies. J. Natl. Cancer Inst. (IF 11.816) Pub Date : 2022-06-20 Audrey Y Jung,Thomas U Ahearn,Sabine Behrens,Pooja Middha,Manjeet K Bolla,Qin Wang,Volker Arndt,Kristan J Aronson,Annelie Augustinsson,Laura E Beane Freeman,Heiko Becher,Hermann Brenner,Federico Canzian,Lisa A Carey,,Kamila Czene,A Heather Eliassen,Mikael Eriksson,D Gareth Evans,Jonine D Figueroa,Lin Fritschi,Marike Gabrielson,Graham G Giles,Pascal Guénel,Andreas Hadjisavvas,Christopher A Haiman,Niclas
BACKGROUND Reproductive factors have been shown to be differentially associated with risk of estrogen receptor (ER) positive and ER-negative breast cancer. However, their associations with intrinsic-like subtypes are less clear. METHODS Analyses included up to 23,353 cases, and 71,072 controls pooled from 31 population-based case-control or cohort studies in the Breast Cancer Association Consortium
-
Can breast cancer prevention strategies be tailored to biologic subtype and unique reproductive windows? J. Natl. Cancer Inst. (IF 11.816) Pub Date : 2022-06-20 Pepper Schedin,Julie R Palmer
-
Correction to: Nitrogen-based Bisphosphonate Use and Ovarian Cancer Risk in Women Aged 50 Years and Older. J. Natl. Cancer Inst. (IF 11.816) Pub Date : 2022-08-08
-
Response to Moskowitz and Birnbaum, Taylor, Baldwin et al. J. Natl. Cancer Inst. (IF 11.816) Pub Date : 2022-06-15 Joachim Schüz,Kirstin Pirie,Gillian K Reeves,Sarah Floud,Valerie Beral
-
Uncovering the Genetic Etiology of the (Posttherapy) Broken Heart. J. Natl. Cancer Inst. (IF 11.816) Pub Date : 2022-08-08 Martha S Linet,Graça M Dores,Sharon A Savage
-
A novel locus on 6p21.2 for cancer treatment-induced cardiac dysfunction among childhood cancer survivors J. Natl. Cancer Inst. (IF 11.816) Pub Date : 2022-06-14 Yadav Sapkota, Matthew J Ehrhardt, Na Qin, Zhaoming Wang, Qi Liu, Weiyu Qiu, Kyla Shelton, Ying Shao, Emily Plyler, Heather L Mulder, John Easton, J Robert Michael, Paul W Burridge, Xuexia Wang, Carmen L Wilson, John L Jefferies, Eric J Chow, Kevin C Oeffinger, Lindsay M Morton, Chunliang Li, Jun J Yang, Jinghui Zhang, Smita Bhatia, Daniel A Mulrooney, Melissa M Hudson, Leslie L Robison, Gregory T
Background Adult survivors of childhood cancer are at increased risk of cardiac late effects. Methods Using whole-genome sequencing data from 1,870 survivors of European ancestry in the St. Jude Lifetime Cohort (SJLIFE) study, genetic variants were examined for association with ejection fraction (EF) and clinically assessed cancer therapy-induced cardiac dysfunction (CCD). Significant findings were
-
Genomic determinants of early recurrences in low-stage low-grade endometrioid endometrial carcinoma J. Natl. Cancer Inst. (IF 11.816) Pub Date : 2022-06-14 Nida S Safdar, Marina Stasenko, Pier Selenica, Axel S Martin, Edaise M da Silva, Ana Paula Martins Sebastiao, Melissa Krystel-Whittemore, Nadeem R Abu-Rustum, Jorge S Reis-Filho, Robert A Soslow, Ronglai Shen, Jennifer J Mueller, Esther Oliva, Britta Weigelt
Low-stage, low-grade endometrioid endometrial carcinoma (EEC), the most common histologic type of endometrial cancer, typically has a favorable prognosis. A subset of these cancers, however, display an aggressive clinical course with early recurrences, including distant relapses. All statistical tests were 2-sided. Using a combination of whole-exome and targeted capture sequencing of 65 FIGO stage
-
Digital Health Applications in Oncology: An Opportunity to Seize J. Natl. Cancer Inst. (IF 11.816) Pub Date : 2022-06-01 Ravi B Parikh, Karen M Basen-Enquist, Cathy Bradley, Deborah Estrin, Mia Levy, J Leonard Lichtenfeld, Bradley Malin, Deven McGraw, Neal J Meropol, Randall A Oyer, Lisa Kennedy Sheldon, Lawrence N Shulman
Digital health advances have transformed many clinical areas including psychiatric and cardiovascular care. However, digital health innovation is relatively nascent in cancer care, which represents the fastest-growing area of health care spending. Opportunities for digital health innovation in oncology include patient-facing technologies that improve patient experience, safety, and patient-clinician
-
Performance of cervical screening a decade following HPV vaccination: The Costa Rica Vaccine Trial. J. Natl. Cancer Inst. (IF 11.816) Pub Date : 2022-05-31 Shang-Ying Hu,Aimée R Kreimer,Carolina Porras,Diego Guillén,Mario Alfaro,Teresa M Darragh,Mark H Stoler,Luis F Villegas,Rebecca Ocampo,Ana Cecilia Rodriguez,Mark Schiffman,Sabrina H Tsang,Douglas R Lowy,John T Schiller,John Schussler,Wim Quint,Mitchell H Gail,Joshua N Sampson,Allan Hildesheim,Rolando Herrero,
BACKGROUND We investigated the impact of HPV vaccination on the performance of cytology-based and HPV-based screening for detection of cervical precancer among women vaccinated as young adults and reaching screening age. METHODS A total of 4632 women aged 25-36 years from the Costa Rica HPV Vaccine Trial were included (2418 HPV-vaccinated as young adults and 2214 unvaccinated). We assessed the performance
-
The Development of Global Cancer Research at the United States National Cancer Institute J. Natl. Cancer Inst. (IF 11.816) Pub Date : 2022-05-31 Mark Parascandola, Paul C Pearlman, Linsey Eldridge, Satish Gopal
International research and collaboration has been a part of the National Cancer Institute’s (NCI) mission since its creation in 1937. Early on, efforts were limited to international exchange of information to ensure that U.S. cancer patients could benefit from advances in other countries. As NCI’s research grant portfolio grew in the 1950s, it included a modest number of grants to foreign institutions
-
The National Cancer Institute Funding of Global Research: Lessons Learned and Opportunities Going Forward. J. Natl. Cancer Inst. (IF 11.816) Pub Date : 2022-05-28 Lawrence N Shulman
-
Correction to: Comparing the Cost-Effectiveness of Innovative Colorectal Cancer Screening Tests. J. Natl. Cancer Inst. (IF 11.816) Pub Date : 2022-07-11
-
Association Between Medicaid Expansion Under the Affordable Care Act and Survival Among Newly Diagnosed Cancer Patients. J. Natl. Cancer Inst. (IF 11.816) Pub Date : 2022-08-08 Xuesong Han,Jingxuan Zhao,K Robin Yabroff,Christopher J Johnson,Ahmedin Jemal
BACKGROUND Medicaid expansion under the Affordable Care Act (ACA) is associated with increased insurance coverage among patients with cancer. Whether these gains translate to improved survival is largely unknown. This study examines changes in 2-year survival among patients newly diagnosed with cancer following the ACA Medicaid expansion. METHODS Patients aged 18-62 years from 42 states' population-based
-
Clinical Benefit Scales and Trial Design: Some Statistical Issues J. Natl. Cancer Inst. (IF 11.816) Pub Date : 2022-05-18 Edward L Korn, Carmen J Allegra, Boris Freidlin
Recently developed clinical-benefit outcome scales by the European Society for Medical Oncology (ESMO) and the American Society of Clinical Oncology (ASCO) allow standardized objective evaluation of outcomes of randomized clinical trials. However, incorporation of clinical-benefit outcome scales into trial designs highlights a number of statistical issues: the relationship between minimal clinical
-
The molecular landscape of pancreatobiliary cancers for novel targeted therapies from real-world genomic profiling J. Natl. Cancer Inst. (IF 11.816) Pub Date : 2022-05-18 Kumiko Umemoto, Hiroyuki Yamamoto, Ritsuko Oikawa, Hiroyuki Takeda, Ayako Doi, Yoshiki Horie, Hiroyuki Arai, Takashi Ogura, Takuro Mizukami, Naoki Izawa, Jay A Moore, Ethan S Sokol, Yu Sunakawa
Background Chemotherapies have limited efficacy in pancreatic cancer (PC) and biliary tract cancer (BTC), underscoring the need for new regimens. Recently, tumor-agnostic approaches have been developed for some targeted therapies in advanced solid tumors, however, the frequency of alterations by clinical and genomic background are unclear in PC and BTC. Methods To assess the frequencies of druggable
-
Benefit of biennial faecal occult blood screening on colorectal cancer in England: A population-based case-control study J. Natl. Cancer Inst. (IF 11.816) Pub Date : 2022-05-16 Alejandra Castanon, Dharmishta Parmar, Nathalie Massat, Peter Sasieni, Stephen W Duffy
Background The English national bowel cancer screening programme(NHSBCSP) offering a guaiac faecal occult blood test (gFOBT) began in July 2006. In randomised controlled trials of gFOBT screening, reductions in mortality were accompanied by reductions in advanced stage colorectal cancer (CRC). We aimed to evaluate the effect of participation in the NHSBCSP on stage-specific CRC incidence, as a likely
-
Impact of HIV on Anal Squamous Cell Carcinoma Rates in the United States, 2001-2015 J. Natl. Cancer Inst. (IF 11.816) Pub Date : 2022-05-16 Elizabeth R Zhang, Ruth M Pfeiffer, April Austin, Megan A Clarke, Jennifer Hayes, Marie-Josèphe Horner, Analise Monterosso, Karen S Pawlish, Eric A Engels, Meredith S Shiels
Background Incidence of anal squamous cell carcinoma (SCC) has increased in the U.S. Persons living with HIV (PLWH) have an elevated risk of anal SCC, and changes in the number of anal SCCs among PLWH may have influenced general population trends. Methods Data were obtained from a linkage of HIV and cancer registries in 12 U.S. regions. The proportion of anal SCCs occurring among PLWH was estimated
-
Improving Patient Advocacy in NCI Scientific Steering Committees and Task Forces. J. Natl. Cancer Inst. (IF 11.816) Pub Date : 2022-08-08 Rick Bangs,Jean M Lynn,Evelyn Obot,Sherill Osborne,Kim Norris
This commentary discusses improving research advocacy as part of National Cancer Institute (NCI) clinical trial activities in scientific steering committees and task forces between 2016 and 2020. Before 2016, the focus of patient advocate input on clinical trial concept evaluation was assessing accrual feasibility. By leveraging informal benchmarking and an outside-in perspective, the NCI patient advocate
-
Persistence of Chemotherapy-Induced Peripheral Neuropathy Despite Vincristine Reduction in Childhood B-Acute Lymphoblastic Leukemia. J. Natl. Cancer Inst. (IF 11.816) Pub Date : 2022-08-08 Rozalyn L Rodwin,John A Kairalla,Emily Hibbitts,Meenakshi Devidas,Moira K Whitley,Caroline E Mohrmann,Reuven J Schore,Elizabeth Raetz,Naomi J Winick,Stephen P Hunger,Mignon L Loh,Marilyn J Hockenberry,Anne L Angiolillo,Kirsten K Ness,Nina S Kadan-Lottick
BACKGROUND Children with B-acute lymphoblastic leukemia (B-ALL) are at risk for chemotherapy-induced peripheral neuropathy (CIPN). Children's Oncology Group AALL0932 randomized reduction in vincristine and dexamethasone (every 4 weeks vs 12 weeks during maintenance in the average-risk subset of National Cancer Institute standard-B-ALL (SR AR B-ALL). We longitudinally measured CIPN, overall and by treatment
-
Disparities in risk of advanced stage liver cancer and mortality by race and ethnicity. J. Natl. Cancer Inst. (IF 11.816) Pub Date : 2022-05-12 Delfino Y Li,Trang VoPham,Mei-Tzu C Tang,Christopher I Li
BACKGROUND In the United States liver cancer is the 5th and 7th most common cause of cancer related-death among men and women, respectively. Compared to other racial/ethnic groups in the U.S. Asian and Pacific Islander populations experience the highest incidence rates of liver cancer, but little is known about disparities in risk of advanced stage disease or risk of liver cancer mortality across these
-
Molecular mechanisms of ARID5B-mediated genetic susceptibility to acute lymphoblastic leukemia J. Natl. Cancer Inst. (IF 11.816) Pub Date : 2022-05-11 Xujie Zhao, Maoxiang Qian, Charnise Goodings, Yang Zhang, Wenjian Yang, Ping Wang, Beisi Xu, Cheng Tian, Ching-Hon Pui, Stephen P Hunger, Elizabeth A Raetz, Meenakshi Devidas, Mary V Relling, Mignon L Loh, Daniel Savic, Chunliang Li, Jun J Yang
Background There is growing evidence for the inherited basis of susceptibility to childhood acute lymphoblastic leukemia (ALL). Genome-wide association studies have identified non-coding ALL risk variants at the ARID5B gene locus, but their exact functional effects and the molecular mechanism linking ARID5B to B-ALL leukemogenesis remain largely unknown. Methods We performed targeted sequencing of
-
The Quest to Eradicate HPV-Related Oropharyngeal Carcinoma: An Opportunity Not to Miss J. Natl. Cancer Inst. (IF 11.816) Pub Date : 2022-05-11 Chloe S Lalonde, Yong Teng, Barbara A Burtness, Robert L Ferris, Rafi Ahmed, Nabil F Saba
Oropharyngeal squamous cell carcinoma (OPSCC) accounts for over half of all head and neck cancers. Since the 1970s, OPSCC has shifted from an environmentally triggered to virally mediated disease due to a sharp rise in human papillomavirus (HPV)-related SCC. Although a highly effective prophylactic vaccine is available, its current implementation is far below national targets and OPSCC incidence is
-
Genome-Wide Interaction Analysis of Genetic Variants With Menopausal Hormone Therapy for Colorectal Cancer Risk. J. Natl. Cancer Inst. (IF 11.816) Pub Date : 2022-08-08 Yu Tian,Andre E Kim,Stephanie A Bien,Yi Lin,Conghui Qu,Tabitha A Harrison,Robert Carreras-Torres,Virginia Díez-Obrero,Niki Dimou,David A Drew,Akihisa Hidaka,Jeroen R Huyghe,Kristina M Jordahl,John Morrison,Neil Murphy,Mireia Obón-Santacana,Cornelia M Ulrich,Jennifer Ose,Anita R Peoples,Edward A Ruiz-Narvaez,Anna Shcherbina,Mariana C Stern,Yu-Ru Su,Franzel J B van Duijnhoven,Volker Arndt,James W Baurley
BACKGROUND The use of menopausal hormone therapy (MHT) may interact with genetic variants to influence colorectal cancer (CRC) risk. METHODS We conducted a genome-wide, gene-environment interaction between single nucleotide polymorphisms and the use of any MHT, estrogen only, and combined estrogen-progestogen therapy with CRC risk, among 28 486 postmenopausal women (11 519 CRC patients and 16 967 participants
-
Minding the Gap: Cancer-Related Survival Disparities in Adolescent and Young Adult Survivors. J. Natl. Cancer Inst. (IF 11.816) Pub Date : 2022-08-08 Danielle Novetsky Friedman,Tara O Henderson
-
Impact of age on clinical outcomes and efficacy of adjuvant dual anti-HER2 targeted therapy J. Natl. Cancer Inst. (IF 11.816) Pub Date : 2022-05-03 Matteo Lambertini, Shona Fielding, Sibylle Loibl, Wolfgang Janni, Emma Clark, Maria Alice Franzoi, Debora Fumagalli, Carmela Caballero, Luca Arecco, Sharon Salomoni, Noam F Ponde, Francesca Poggio, Hee Jeong Kim, Cynthia Villarreal-Garza, Olivia Pagani, Shani Paluch-Shimon, Alberto Ballestrero, Lucia Del Mastro, Martine Piccart, Jose Bines, Ann H Partridge, Evandro de Azambuja
Background Young age at breast cancer (BC) diagnosis has historically been a rationale for overtreatment. Limited data with short follow-up exist on the prognostic value of age at diagnosis in HER2-positive BC and the benefit of anti-HER2 therapy in young patients. Methods APHINITY (NCT01358877) is an international, placebo-controlled, double-blind randomized phase III trial in HER2-positive early
-
Genetic Analysis of Lung Cancer and the Germline Impact on Somatic Mutation Burden. J. Natl. Cancer Inst. (IF 11.816) Pub Date : 2022-08-08 Aurélie A G Gabriel,Joshua R Atkins,Ricardo C C Penha,Karl Smith-Byrne,Valerie Gaborieau,Catherine Voegele,Behnoush Abedi-Ardekani,Maja Milojevic,Robert Olaso,Vincent Meyer,Anne Boland,Jean François Deleuze,David Zaridze,Anush Mukeriya,Beata Swiatkowska,Vladimir Janout,Miriam Schejbalová,Dana Mates,Jelena Stojšić,Miodrag Ognjanovic,,John S Witte,Sara R Rashkin,Linda Kachuri,Rayjean J Hung,Siddhartha
BACKGROUND Germline genetic variation contributes to lung cancer (LC) susceptibility. Previous genome-wide association studies (GWAS) have implicated susceptibility loci involved in smoking behaviors and DNA repair genes, but further work is required to identify susceptibility variants. METHODS To identify LC susceptibility loci, a family history-based genome-wide association by proxy (GWAx) of LC
-
Subsequent primary cancer risk among five-year survivors of adolescent and young adult cancers J. Natl. Cancer Inst. (IF 11.816) Pub Date : 2022-04-26 Hyuna Sung, Rebecca L Siegel, Noorie Hyun, Kimberly D Miller, K Robin Yabroff, Ahmedin Jemal
Background A comprehensive examination of the incidence and mortality of subsequent primary cancers (SPCs) among adolescent and young adult (AYA) cancer survivors in the US is lacking. Methods Cancer incidence and mortality among 170,404 ≥ 5-year cancer survivors aged 15–39 years at first primary cancer diagnosis during 1975–2013 in 9 Surveillance, Epidemiology, and End Results registries were compared
-
RE: Nitrogen-Based Bisphosphonate Use and Ovarian Cancer Risk in Women Aged 50 Years and Older J. Natl. Cancer Inst. (IF 11.816) Pub Date : 2022-04-23 Steven Lehrer,Peter H Rheinstein
-
Response to Lehrer and Rheinstein J. Natl. Cancer Inst. (IF 11.816) Pub Date : 2022-04-23 Karen M Tuesley,Penelope M Webb,Melinda M Protani,Katrina Spilsbury,Sallie-Anne Pearson,Michael D Coory,Peter Donovan,Christopher Steer,Louise M Stewart,Nirmala Pandeya,Susan J Jordan
-
An Evaluation of Sex- and Gender-Based Analyses in Oncology Clinical Trials J. Natl. Cancer Inst. (IF 11.816) Pub Date : 2022-04-22 Mathew Hall, Vaishali A Krishnanandan, Matthew C Cheung, Natalie G Coburn, Barbara Haas, Kelvin K W Chan, Michael J Raphael
Background The objective of this study was to evaluate whether sex- and gender-based analyses and proper sex- and gender-terminology were used in oncology trials leading to regulatory drug approval. Methods The Food and Drug Administration (FDA) Hematology/Oncology Approvals and Safety Notifications page was used to identify all anti-cancer therapies that received FDA approval between 2012 and 2019
-
Banning Menthol Cigarettes: The Time Has Come. J. Natl. Cancer Inst. (IF 11.816) Pub Date : 2022-07-11 Andrew L Pipe
-
Synonymous Variants: Necessary Nuance in our Understanding of Cancer Drivers and Treatment Outcomes J. Natl. Cancer Inst. (IF 11.816) Pub Date : 2022-04-21 Nayiri M Kaissarian, Douglas Meyer, Chava Kimchi-Sarfaty
Once called “silent mutations” and assumed to have no effect on protein structure and function, synonymous variants are now recognized to be drivers for some cancers. There have been significant advances in our understanding of the numerous mechanisms by which synonymous single nucleotide variants (sSNVs) can affect protein structure and function by affecting pre-mRNA splicing, mRNA expression, stability
-
Association of Medical Financial Hardship and Mortality Among Cancer Survivors in the United States. J. Natl. Cancer Inst. (IF 11.816) Pub Date : 2022-06-13 K Robin Yabroff,Xuesong Han,Weishan Song,Jingxuan Zhao,Leticia Nogueira,Craig E Pollack,Ahmedin Jemal,Zhiyuan Zheng
BACKGROUND Cancer survivors frequently experience medical financial hardship in the United States. Little is known, however, about long-term health consequences. This study examines the associations of financial hardship and mortality in a large nationally representative sample of cancer survivors. METHODS We identified cancer survivors aged 18-64 years (n = 14 917) and 65-79 years (n = 10 391) from
-
Helicobacter pylori Modulated Host Immunity in Gastric Cancer Patients With S-1 Adjuvant Chemotherapy. J. Natl. Cancer Inst. (IF 11.816) Pub Date : 2022-08-08 Yuka Koizumi,Sheny Ahmad,Miyuki Ikeda,Akiko Yashima-Abo,Ginny Espina,Ryo Sugimoto,Tamotsu Sugai,Takeshi Iwaya,Gen Tamura,Keisuke Koeda,Lance A Liotta,Fumiaki Takahashi,Satoshi S Nishizuka,
BACKGROUND Paradoxically, Helicobacter pylori-positive (HP+) advanced gastric cancer patients have a better prognosis than those who are HP-negative (HP-). Immunologic and statistical analyses can be used to verify whether systemic mechanisms modulated by HP are involved in this more favorable outcome. METHODS A total of 658 advanced gastric cancer patients who underwent gastrectomy were enrolled.
-
Charting a Path Towards Asian American Cancer Health Equity: A Way Forward. J. Natl. Cancer Inst. (IF 11.816) Pub Date : 2022-06-13 Moon S Chen,Richard J Lee,Ravi A Madan,Van Ta Park,Susan M Shinagawa,Tracy Sun,Scarlett L Gomez
On July 29, 2021, the US Food and Drug Administration's Oncology Center of Excellence convened Conversations on Cancer. This Conversation, the first ever by the US Food and Drug Administration, focused on Asian Americans and served as the platform for this Commentary. Panelists elaborated on topics ranging from heterogeneity in Asian American demographics to racism through a path to health equity and
-
Pancreatic Ductal Carcinoma Risk Associated with Hereditary Cancer-Risk Genes J. Natl. Cancer Inst. (IF 11.816) Pub Date : 2022-04-19 Anna Gardiner, John Kidd, Maria C Elias, Kayla Young, Brent Mabey, Nassim Taherian, Shelly Cummings, Mokenge Malafa, Eric Rosenthal, Jennifer B Permuth
Background Although several hereditary cancer predisposition genes have been implicated in pancreatic ductal adenocarcinoma (PDAC) susceptibility, gene-specific risks are not well defined, and are potentially biased due to the design of previous studies. More precise and unbiased risk estimates can result in screening and prevention better tailored to genetic findings. Methods This is a retrospective
-
Biological and Molecular Factors Predicting Response to Adoptive Cell Therapies in Cancer J. Natl. Cancer Inst. (IF 11.816) Pub Date : 2022-04-15 Gerardo Ferrer, Damiana Álvarez-Errico, Manel Esteller
Adoptive cell therapy (ACT) constitutes a major breakthrough in cancer management that has expanded in the past years due to impressive results showing durable and even curative responses for some patients with hematological malignancies. ACT leverages antigen specificity and cytotoxic mechanisms of the immune system, particularly relying on the patient´s T lymphocytes to target and eliminate malignant
-
Smoking Quit Rates Among Menthol vs Non-Menthol Smokers: Implications Regarding a US Ban on the Sale of Menthol Cigarettes J. Natl. Cancer Inst. (IF 11.816) Pub Date : 2022-04-14 Heather M Munro, Martha J Shrubsole, Wei Zheng, Wanqing Wen, William J Blot
Background A ban on the sale of menthol cigarettes in the United States is currently under consideration. A justification is that menthol cigarettes are harder to quit, particularly for African American smokers who use menthols much more frequently than White smokers, but epidemiologic data are limited. Methods In a cohort of 16,425 mostly low income African American and White current cigarette smokers
-
Policies and Practices to Address Cancer’s Long-term Adverse Consequences J. Natl. Cancer Inst. (IF 11.816) Pub Date : 2022-04-14 Cathy J Bradley, Sara Kitchen, Smita Bhatia, Julie Bynum, Gwen Darien, J Leonard Lichtenfeld, Randall Oyer, Lawrence N Shulman, Lisa Kennedy Sheldon
As cancer detection and treatment improve, the number of long-term survivors will continue to grow, as will the need to improve their survivorship experience and health outcomes. We need to better understand cancer and its treatment’s short- and long-term adverse consequences, and to prevent, detect, and treat these consequences effectively. Delivering care through a collaborative care model, standardizing
-
Body size at different ages and risk of six cancers: a Mendelian randomization and prospective cohort study J. Natl. Cancer Inst. (IF 11.816) Pub Date : 2022-04-14 Daniela Mariosa, Karl Smith-Byrne, Tom G Richardson, Pietro Ferrari, Marc J Gunter, Nikos Papadimitriou, Neil Murphy, Sofia Christakoudi, Konstantinos K Tsilidis, Elio Riboli, David Muller, Mark P Purdue, Stephen J Chanock, Rayjean J Hung, Christopher I Amos, Tracy A O'Mara, Pilar Amiano, Fabrizio Pasanisi, Miguel Rodriguez-Barranco, Vittorio Krogh, Anne Tjønneland, Jytte Halkjær, Aurora Perez-Cornago
It is unclear if body weight in early life affects cancer risk independently of adult body weight. To investigate this question for six obesity-related cancers, we performed univariable and multivariable analyses using i) Mendelian randomization (MR) analysis and ii) longitudinal analyses in prospective cohorts. Both the MR and longitudinal analyses indicated that larger body size at age 10 was associated
-
Cardiovascular and Metabolic Diagnoses Associated With Novel Hormonal Agents for Prostate Cancer in Nontrial Populations. J. Natl. Cancer Inst. (IF 11.816) Pub Date : 2022-08-08 Nancy L Keating
-
COVID-19 Sequelae and the Host Proinflammatory Response: An Analysis From the OnCovid Registry. J. Natl. Cancer Inst. (IF 11.816) Pub Date : 2022-07-11 Alessio Cortellini,Alessandra Gennari,Fanny Pommeret,Grisma Patel,Thomas Newsom-Davis,Alexia Bertuzzi,Margarita Viladot,Juan Aguilar-Company,Oriol Mirallas,Eudald Felip,Alvin J X Lee,Alessia Dalla Pria,Rachel Sharkey,Joan Brunet,MCarmen Carmona-García,John Chester,Uma Mukherjee,Lorenza Scotti,Saoirse Dolly,Ailsa Sita-Lumsden,Daniela Ferrante,Mieke Van Hemelrijck,Charlotte Moss,Beth Russell,Elia Seguí
BACKGROUND Fifteen percent of patients with cancer experience symptomatic sequelae, which impair post-COVID-19 outcomes. In this study, we investigated whether a proinflammatory status is associated with the development of COVID-19 sequelae. METHODS OnCovid recruited 2795 consecutive patients who were diagnosed with Severe Acute Respiratory Syndrome Coronavirus 2 infection between February 27, 2020